FABP1 and metabolic dysfunction-associated steatotic liver disease: Further indication that FABP1 may be involved in the development of nonalcoholic fatty liver disease and NASH comes from a study showing that activation of the glucagon-like peptide-1 receptor reduces oleate-induced steatosis in HepG2 cells by reducing FA uptake and transport via FABP1 downregulation (86).